Deaf Kids Hear Again! 'Amazing' Gene Therapy Restores Hearing For Years

A groundbreaking new gene therapy is offering a ray of hope to children and adults battling inherited deafness. Trials show this incredible treatment can restore hearing for years. A staggering 90 percent of recipients saw improvements, with half achieving normal levels of hearing.

A 'Paradigm Shift' in Treatment

This revolutionary experimental treatment, targeting a rare form of genetic deafness, has successfully restored hearing in young patients and adults. The improvements have lasted for at least two and a half years, according to a study published on April 22, 2026, in Nature.

The research was co-led by investigators from Harvard Medical School at Massachusetts Eye and Ear and the Eye & ENT Hospital of Fudan University in China. It focused on correcting mutations in the OTOF gene, which causes deafness from birth.

Younger patients, aged 18 and under, experienced the most significant gains in hearing and speech recognition. Adults also saw improvements, though to a lesser extent.

Zheng-Yi Chen, a co-senior author of the paper from Harvard Medical School, called the results 'really amazing'. He added: “After two and a half years, more than half of them reached a normal level. They can hear a whisper. At that level, it’s better than mine.”

Around 430 million people worldwide are affected by hearing loss severe enough to require rehabilitation, including 34 million children. Genetic causes are behind 60 percent of deafness in newborns, with the OTOF gene mutation accounting for two to eight percent of these cases.

Babies born with the OTOF mutation are completely deaf, which can hinder speech acquisition and cognitive development without early intervention like cochlear implants. Currently, no approved drugs exist to treat OTOF mutations or other forms of congenital deafness.

Yilai Shu, another co-senior author from Fudan University and a former HMS postdoctoral fellow, stated: “The success of OTOF gene therapy marks a paradigm shift in treating hearing loss.” He believes this trial proves that personalised gene therapy approaches can be developed for various types of congenital deafness.

In fact, researchers are already working on modifying the platform to treat deafness caused by mutations in the GJB2 gene, which is the most common genetic cause of hearing loss.

How Does it Work?

The therapy targets a condition known as DFNB9, caused by the OTOF mutation. This gene is crucial for producing the otoferlin protein, which is active in the cochlea, the snail-shaped structure in the inner ear.

Otoferlin helps translate sound waves into electrical signals that are sent to nerves and the brain. Without properly functioning otoferlin, these vital electrical pulses never reach the brain.

To correct this, the team injects a neutralised virus, carrying a normal copy of the OTOF gene, into the fluid of the inner ear. The virus then travels to the cochlea, expressing the OTOF gene in hair cells.

This process kick-starts the production of normal otoferlin, restoring the crucial connection between the cochlea and the nerves leading to the brain.

Promising results showed some participants heard sound within just two weeks. Improvement was rapid for the first six weeks, stabilising around 26 weeks, with hearing recovery sustained for two and a half years.

Hopes for the Future

This trial, the largest and longest follow-up for inherited hearing loss gene therapy to date, involved 42 participants aged nine months to 32 years across eight sites in China.

It builds on earlier research from 2024, which showed rapid improvements in a small number of children, thrilling parents as their kids went from complete deafness to responding to voices within weeks.

Shu shared the joy of seeing their progress: “As follow-up time goes on, these children continue to bring us ongoing surprises. They progress from responding to sounds, to imitating speech, to speaking in short sentences, and then to reciting poems and even singing. They always fill us with joy and encouragement.”

Significantly, the treatment proved safe, with no serious adverse events reported among participants.

Researchers will continue to monitor participants for five years. They are now exploring the regulatory requirements to get the treatment approved for clinical use, starting in China, with hopes for expansion to other countries, including the United States.

Chen expressed optimism for the future: “We have been working in this field for decades and there was nothing, nothing, nothing. Then the treatment came out, worked really well, and now more trials are coming. We’re looking forward to what the future will bring for patients.”

Related Content

MORE: Wife discovers husband’s ‘secret life’ on dating show after five years of marriage — https://trendwiremedia.com/2026/02/04/wife-discovers-husbands-secret-life-on-dating-show-after-five-years-of-marriage/

MORE: Unborn babies to get life-saving "super cells" from mums in world-first trial — https://trendwiremedia.com/2026/03/13/unborn-babies-to-get-life-saving-super-cells-from-mums-in-world-first-trial/

MORE: Serial rapist from Bristol jailed for 19 years following Surrey and Bristol attacks — https://trendwiremedia.com/2026/03/20/serial-rapist-from-bristol-jailed-for-19-years-following-surrey-and-bristol-attacks/

OFFICIAL SOURCE VERIFICATION: This report is based on official data from University Newsroom. Document: [Hearing Restoration From Gene Therapy for Inherited Deafness Lasts Years, New Trial Results Show](https://hms.harvard.edu/news/hearing-restoration-gene-therapy-inherited-deafness-lasts-years-new-trial-results-show) Source Link: https://hms.harvard.edu/news/hearing-restoration-gene-therapy-inherited-deafness-lasts-years-new-trial-results-show